Home » HEART STENT REVENUES REDUCE ANGIOTECH EARNINGS
HEART STENT REVENUES REDUCE ANGIOTECH EARNINGS
Lower revenues from its partner in the heart stent business dropped Angiotech Pharmaceuticals Inc. profits in the first quarter to $7.5 million (U.S.) from a year-ago $18.8 million, the company reported Tuesday.
The
Toronto Star
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May